CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with Clinical Trials in 2021 after Receiving FDA Approval for IND for Berubicin
The company is scheduled to conduct three clinical trials in 2021 for Berubicin – two Phase II and the first-ever…